Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens

被引：9

作者：

Stein, Gary E. ^{[1
]}

Schooley, Sharon ^{[1
]}

Tyrrell, Kerin L. ^{[2
]}

Citron, Diane M. ^{[2
]}

Nicolau, David P. ^{[3
]}

Goldstein, Ellie J. C. ^{[2
,4
]}

机构：

[1] Michigan State Univ, Dept Med, E Lansing, MI 48824 USA

[2] RM Alden Res Lab, Santa Monica, CA 90404 USA

[3] Hartford Hosp, Ishikari, Hokkaido 06102, Japan

[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA

来源：

ANAEROBE | 2008年 / 14卷 / 01期

关键词：

moxifloxacin; levofloxacin; anaerobes; intra-abdominal; bacteroides;

D O I：

10.1016/j.anaerobe.2007.09.005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We studied the serum bactericidal activity (SBA) of moxifloxacin and levofloxacin against common pathogens associated with complicated intra-abdominal infections. Ten healthy volunteers received a single dose of moxifloxacin (400 mg) and levofloxacin (750 mg) and serum samples were collected at 2, 4, 8, 12, and 24h after the dose of each drug. Bactericidal titers in serum over time were determined for aerobic gram-negative bacilli (Escherichia coli, Klebseilla pneutnoniae, and Enterobacter cloacae) and anaerobic bacteria (Bacteroides fi-agilis.. Bacteroides thetaiotaomicron, Prevotella bivia, and Finegoldia magna). Both fluoroquinolones provided rapid (2 h) attainment and prolonged (24 h) SBA (titers >= 1:8) against each of the aerobic bacilli studied. SBA was observed for at least 12 h against B. fragilis strains with MICs <= 2 mu g/ml to moxifloxacin and <= 4 mu g/ml to levofloxacin. Prolonged (12 h) SBA (titers >= 1:2) was also observed against isolates of B. thetaiotaoinicron, P. bivia, and F magna with moxifloxacin MICs <= 2 mu g/ml. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：8 / 12

页数：5

共 22 条

[1] Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers [J].

Chien, SC ;

Wong, FA ;

Fowler, CL ;

Callery-D'Amico, SV ;

Williams, RR ;

Nayak, R ;

Chow, AT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :885-888

[2]

*CLIN LAB STAND I, 2004, M11A6 CLSI

[3]

*CLIN LAB STAND I, 2003, M7A6 CLSI

[4]

Clinical Laboratory Standards Institute, 1999, M21A CLSI

[5] In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections [J].

Edmiston, CE ;

Krepel, CJ ;

Seabrook, GR ;

Somberg, LR ;

Nakeeb, A ;

Cambria, RA ;

Towne, JB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :1012-1016

[6] Use of modeling techniques to aid in antibiotic selection [J].

Alexander A. Firsov ;

Stephen H. Zinner .

Current Infectious Disease Reports, 2001, 3 (1) :35-43

[7] Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae [J].

Florea, NR ;

Tessier, PR ;

Zhang, CL ;

Nightingale, CH ;

Nicolau, DP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1215-1221

[8] In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections [J].

Goldstein, EJC ;

Citron, DM ;

Warren, YA ;

Tyrrell, KL ;

Merriam, CV ;

Fernandez, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :148-155

[9] Effect of serum from different patient populations on the serum bactericidal test [J].

Kays, MB ;

White, RL ;

Friedrich, LV .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (03) :417-420

[10] Fluoroquinolone prescribing in the United States: 1995 to 2002 [J].

Linder, JA ;

Huang, ES ;

Steinman, MA ;

Gonzales, R ;

Stafford, RS .

AMERICAN JOURNAL OF MEDICINE, 2005, 118 (03) :259-268

← 1 2 3 →